ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled โDeucrictibant: Beyond HAE Type 1/2โ on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET.
The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated angioedema, the potential of deucrictibant to address those unmet needs, and Pharvarisโ biomarker approach to identification of those living with bradykinin-mediated angioedema and other diseases.
Presenters of the event are:
- Danny M. Cohn, M.D., Ph.D., Department of Vascular Medicine, Amsterdam UMC (an accredited center of ACARE)
- Anne Lesage, Ph.D., Chief Early Development Officer, Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris
- Berndt Modig, Chief Executive Officer, Pharvaris
To register for the live webcast, please visitย https://ir.pharvaris.com/news-events/events-presentationsย in the News and Events section of the companyโs website. Following the live webcast, an archived replay will be available for at least 30 days after the event.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacyโข and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.
Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications maggie.beller@pharvaris.com
